Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New advances in hepatitis C therapy

    Project Inform Perspective
    |August 13, 2002
    PubMed
    Summary

    New pegylated interferon (PEG-Intron) demonstrates superior efficacy for hepatitis C virus (HCV) treatment compared to standard interferon-alfa. This enhanced drug formulation maintains longer activity in the bloodstream, offering improved therapeutic potential for HCV patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Everything antiretroviral: 5th IAS conference, Cape Town, South Africa.

    Project Inform perspective·2012
    Same journal

    Well implemented, President Obama's national HIV/AIDS strategy is precisely what is needed to further control HIV/AIDS.

    Project Inform perspective·2011
    Same journal

    Finding health care; preparing for the future.

    Project Inform perspective·2011
    Same journal

    Protecting people with HIV in the California budget.

    Project Inform perspective·2010
    Same journal

    Current drugs in clinical study.

    Project Inform perspective·2010
    Same journal

    HIV treatment information.

    Project Inform perspective·2010

    Area of Science:

    • Hepatology
    • Virology
    • Pharmacology

    Background:

    • Hepatitis C virus (HCV) infection remains a significant global health concern.
    • Current interferon-alfa therapies for HCV have limitations in efficacy and duration of action.
    • Development of improved antiviral agents is crucial for effective HCV management.

    Discussion:

    • Pegylated interferon (PEG-Intron) represents a novel formulation of interferon-alfa designed for sustained therapeutic effect.
    • The conjugation of polyethylene glycol to interferon-alfa enhances its pharmacokinetic profile, leading to prolonged blood circulation.
    • Early findings suggest PEG-Intron exhibits greater antiviral activity compared to conventional interferon-alfa.

    Key Insights:

    • PEG-Intron demonstrates improved efficacy in treating hepatitis C virus (HCV) infection.
    • The drug's extended half-life, due to polyethylene glycol conjugation, allows for longer-lasting antiviral action.
    • Comparative studies indicate superior performance of pegylated interferon over standard interferon-alfa therapy.

    Outlook:

    • Pegylated interferon formulations are poised to become a cornerstone in HCV treatment regimens.
    • Further clinical trials are expected to solidify the role of PEG-Intron in achieving higher sustained virologic response rates.
    • Advancements in interferon pegylation may lead to optimized dosing and reduced treatment-related side effects.

    Related Experiment Videos